INS and Hypoglycemia: Current research supports the use of GLP1-RA in combination with a lower dose of insulin to more effectively reduce HbA1c while mitigating weight gain from insulin and lowering the risk of hypoglycemia, all with no change in adverse gastrointestinal issues from the use of GLP1-RA independently [50].